On this episode of the SO files, Brad and Linda cover the recently published trials on adjuvant options for melanoma, including the COMBI-AD trial and the CHECKMATE-238 trial. As a very special guest, they'll be interviewing Dr. Robert Andtbacka, Associate Professor of Surgery at the University of Utah, co-author of the recently published MSLT II trial, panel member of the NCCN guidelines on Melanoma, and lead investigator in the use of viral oncolytic therapy "T-VEC". Given these new results, how will our approach to completion lymph node dissection and adjuvant therapy change in patients with advanced melanoma?